Thus, tolterodine exposure in the carcinogenicity studies was 9- to 14-fold higher than expected in humans.

No differences in the safety profile of tolterodine were identified based on age, gender, race, or metabolism.The data described below reflect exposure to Detrol 2 mg bid in 986 patients and to placebo in 683 patients exposed for 12 weeks in five Phase 3, controlled clinical studies.

Unfortunately, Harvard Health News reports that some supplements taste so bad that patients don't take them regularly enough to make a difference. There appeared to be a greater QTc interval increase in CYP2D6 poor metabolizers than in CYP2D6 extensive metabolizers after tolterodine treatment in this study.This study was not designed to make direct statistical comparisons between drugs or dose levels. Therefore, Detrol should be used during pregnancy only if the potential benefit for the mother justifies the potential risk to the fetus.Tolterodine is excreted into the milk in mice. However, the confidence intervals overlapped.Tolterodine's effect on QT interval was found to correlate with plasma concentration of tolterodine. Symptoms from a small drop in body potassium may include: Mean serum concentrations of tolterodine and the 5-hydroxymethyl metabolite in these elderly volunteers were approximately 20% and 50% higher, respectively, than reported in young healthy volunteers. There has been no association of Torsade de Pointes in the international post-marketing experience with Detrol or Detrol LA (see Detrol Tablets were evaluated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in four randomized, double-blind, placebo-controlled, 12-week studies. The mean increase of heart rate associated with a 4 mg/day dose of tolterodine in this study was 2.0 beats/minute and 6.3 beats/minute with 8 mg/day tolterodine. The change in heart rate with moxifloxacin was 0.5 beats/minute.The reason for the difference between machine and manual read of QT interval is unclear.The QT effect of tolterodine immediate release tablets appeared greater for 8 mg/day (two times the therapeutic dose) compared to 4 mg/day. There was a 52% decrease in CTolterodine immediate release does not cause clinically significant interactions with other drugs metabolized by the major drug metabolizing CYP enzymes. In some cases, your healthcare professional may recommend a special kind of diuretic called potassium-sparing diuretics. Bottles of 500 If you're on the type of diuretics that promote the loss of potassium, your health care provider will monitor your levels closely. This decreased volume, in turn, reduces the amount of “pushing” caused by the blood on the artery walls, leading to a decrease in blood pressure. Diuretic medications can be found in both over-the-counter and prescription forms. QT interval was measured manually and by machine, and data from both are presented. The 4 mg BID dose of tolterodine IR (two times the highest recommended dose) was chosen because this dose results in tolterodine exposure similar to that observed upon coadministration of tolterodine 2 mg BID with potent CYP3A4 inhibitors in patients who are CYP2D6 poor metabolizers (see Table 2 summarizes the mean change from baseline to steady state in corrected QT interval (QTc) relative to placebo at the time of peak tolterodine (1 hour) and moxifloxacin (2 hour) concentrations. For patients with significantly reduced hepatic or renal function or who are currently taking drugs that are potent inhibitors of CYP3A4, the recommended dose of Detrol is 1 mg twice daily (see Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature] (DTL).This product's label may have been updated. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and renin inhibitors are all commonly prescribed to help lower blood pressure and they, in contrast, actually increase potassium levels.

Contraindications. Unlike other "water pills," they do not increase the amount of potassium lost from the body. Symptoms from a large drop in body potassium may include:

The identified pathway of metabolism for these individuals ("poor metabolizers") is dealkylation via cytochrome P450 3A4 (CYP3A4) to A summary of mean (± standard deviation) pharmacokinetic parameters of tolterodine immediate release and the 5-hydroxymethyl metabolite in extensive (EM) and poor (PM) metabolizers is provided in Table 1. For current full prescribing information, please visit Detrol LA (tolterodine tartrate extended release capsules) did not help the symptoms of overactive bladder when studied in children.Overactive bladder happens when you cannot control your bladder muscle. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and approximating rates.Sixty-six percent of patients receiving Detrol 2 mg bid reported adverse events versus 56% of placebo patients. No increase in tumors was found in either mice or rats.No mutagenic effects of tolterodine were detected in a battery of In female mice treated for 2 weeks before mating and during gestation with 20 mg/kg/day (corresponding to AUC value of about 500 µg∙h/L), neither effects on reproductive performance or fertility were seen.